



2/1/2023

Dear University of Arkansas System Member,

**MedImpact Healthcare Systems, Inc.**, (MedImpact) on behalf of the University of Arkansas System Health Plan, will be implementing a change to the prescription benefit plan that affects you. **Please continue to read this entire letter.**

**Effective April 1, 2023, OMNIPOD 5 G6 PODS (GEN 5), OMNIPOD DASH PODS (GEN 4), OMNIPOD CLASSIC PODS (GEN 3) will be subject to a quantity limit of 10 PODS PER 30 DAYS under the prescription benefit plan. You are receiving this letter because our records indicate you had a prescription filled for OMNIPOD 5 G6 PODS (GEN 5), OMNIPOD DASH PODS (GEN 4), OMNIPOD CLASSIC PODS (GEN 3) within the last 120 days.** If you are not currently taking this medication, this notice does not apply to you.

You may be able to continue to receive the current prescription quantity through a prior authorization exception process. To allow sufficient time for you to discuss this change with your physician, coverage for **OMNIPOD 5 G6 PODS (GEN 5), OMNIPOD DASH PODS (GEN 4), OMNIPOD CLASSIC PODS (GEN 3)** without this quantity limit will be extended to **April 1, 2023**. To request coverage, your doctor must submit the appeal form and required medical documentation to EBRx by fax to 1-877-540-9036.

Pharmacy benefits are subject to terms, conditions and eligibility as outlined in the benefit documentation in effect at the time services are provided. The above change to your prescription benefit plan is directed by the University's Pharmacy Advisory Committee.

For questions, please contact MedImpact Healthcare Systems, Inc. at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

*The University of Arkansas System's' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.*